318 related articles for article (PubMed ID: 23775053)
1. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
[TBL] [Abstract][Full Text] [Related]
2. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
4. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
7. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
[TBL] [Abstract][Full Text] [Related]
8. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
9. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
van Kooten M; Arends J; Cohen D
J Clin Psychopharmacol; 2011 Feb; 31(1):126-8. PubMed ID: 21192158
[No Abstract] [Full Text] [Related]
10. Reversal of symptomatic hyperprolactinemia by aripiprazole.
Wahl R; Ostroff R
Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
[No Abstract] [Full Text] [Related]
11. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
12. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
[No Abstract] [Full Text] [Related]
13. Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Anandarajan T; Tibrewal P; Dhillon R; Bastiampillai T
Aust N Z J Psychiatry; 2012 Aug; 46(8):792-3. PubMed ID: 22528973
[No Abstract] [Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
15. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Chen CY; Lin TY; Wang CC; Shuai HA
Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
18. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]